Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus: p27 Antigen Detection and Diagnostic Interpretation

Introduction

Feline leukemia virus (FeLV) is a gammaretrovirus of domestic cats that induces a spectrum of outcomes ranging from transient abortive infection to persistent progressive viremia associated with immunosuppression, anemia, and neoplasia [1, 2]. The viral capsid protein p27 is the most abundant structural antigen produced during active viral replication and serves as the primary target for immunodiagnostic assays [3]. Detection of p27 in blood, serum, plasma, or saliva by enzyme-linked immunosorbent assay (ELISA) constitutes the cornerstone of FeVL screening and clinical staging worldwide [4, 5].

This article provides an exhaustive technical review of the ELISA format for FeLV p27 antigen detection, the biophysical basis of the assay, the biological interpretation of positive and negative results in the context of progressive versus regressive infection, and the performance characteristics derived from peer-reviewed literature. The discussion is restricted strictly to veterinary diagnostics and draws exclusively on published studies of FeLV in domestic cats.

Biology of p27 and Its Role as a Diagnostic Target

FeLV encodes a single-stranded RNA genome approximately 8.5 kb in length. The gag gene encodes the precursor polyprotein Pr65Gag, which is proteolytically cleaved by the viral protease to yield the matrix (p15), capsid (p27), and nucleocapsid (p10) proteins [3]. The p27 capsid protein forms the core shell surrounding the viral RNA and is released into the bloodstream during active viral replication both as free protein and incorporated into intact virions [6, 3].

The concentration of p27 in serum correlates directly with the level of plasma viremia. In progressive infection, p27 is continuously detectable after the first 2-4 weeks post exposure, whereas in regressive infection, p27 may become undetectable after an initial transient antigenemia as the host immune response suppresses viral replication [2, 3]. P27 can also be detected in saliva and tears, enabling noninvasive sampling for diagnostic purposes [6].

ELISA Principle for p27 Detection

All commercial and laboratory-developed ELISAs for FeLV p27 follow a double-antibody sandwich format. The essential steps are as follows:

1. Capture: A monoclonal or polyclonal antibody specific for p27 is immobilized on a solid phase (typically a 96-well microtiter plate or a nitrocellulose membrane in point-of-care devices).

2. Sample incubation: Serum, plasma, whole blood, or saliva is added. p27 present in the sample binds to the capture antibody.

3. Detection antibody: After washing to remove unbound material, a second antibody conjugated to an enzyme (e.g., horseradish peroxidase or alkaline phosphatase) is added. This detection antibody binds to a different epitope on p27, forming a sandwich.

4. Substrate addition: A chromogenic or fluorogenic substrate is introduced. The enzyme catalyzes a color change proportional to the amount of bound p27.

5. Signal measurement: Optical density (OD) is measured at a specific wavelength using a spectrophotometer, or a visual color change is interpreted in the case of lateral flow devices [5].

The analytical sensitivity (limit of detection) for p27 ELISA is typically reported in the range of 1-10 ng/mL of p27, depending on the antibody pair and amplification system [3].

Table 1: Key Reagents and Format of p27 Sandwich ELISA

Diagnostic Interpretation: Progressive versus Regressive Infection

The presence of p27 antigen in a single sample must be interpreted in the context of the cat’s clinical status and history. FeLV infection outcomes are classified as:

• Abortive infection: No p27 detectable; virus cleared rapidly; no proviral integration.
• Regressive infection: Transient p27 antigenemia (usually detectable for 2-4 weeks) followed by clearance of p27 from blood. Proviral DNA remains integrated in hematopoietic cells but is transcriptionally silent. These cats are negative on p27 ELISA but positive on proviral PCR [2, 3].
• Progressive infection: Persistent p27 antigenemia beyond 4-6 weeks. These cats remain p27-positive on ELISA and are at high risk for FeLV-associated disease [1, 2, 3].
• Focal infection: Rare; p27 may be detectable only in certain tissues; blood ELISA often negative.

Thus, a positive p27 ELISA result indicates active viral replication but does not definitively distinguish progressive from regressive infection without follow-up testing. The standard diagnostic algorithm therefore recommends repeat testing 4-6 weeks after an initial positive result to confirm persistent antigenemia [2, 4].

Mermaid Decision Tree for FeLV p27 ELISA Interpretation

flowchart TD
 A[Initial p27 ELISA] --> B{Result?}
 B -->|Negative| C["Low risk; consider PCR if high suspicion"]
 B -->|Positive| D[Confirm with repeat ELISA in 4-6 weeks]
 D --> E{Repeat result?}
 E -->|Negative| F[Regressive infection likely]
 E -->|Positive| G[Progressive infection confirmed]
 G --> H["Monitor for disease; consider antiviral therapy"]
 F --> I[Proviral PCR to confirm regressive infection]

Sensitivity and Specificity of p27 ELISA

Several studies have evaluated the diagnostic accuracy of p27 ELISA in comparison with virus isolation, immunofluorescence, and PCR. Lopez et al. (1989) reported that commercial ELISA kits had sensitivity ranging from 83% to 100% and specificity from 97% to 100% when using virus isolation as the gold standard [5]. Lutz et al. (1983) demonstrated that monoclonal antibody-based ELISA could detect p27 at concentrations as low as 2-5 ng/mL, with no cross-reactivity against other feline retroviruses [3].

The use of saliva as an alternative sample matrix was investigated by Lewis et al. (1987), who found that p27 antigen was detectable in saliva samples with 92% sensitivity and 99% specificity compared to serum ELISA [6]. Saliva sampling is less invasive but may yield lower antigen concentrations, necessitating assay modifications or concentration steps.

False-positive results can arise from nonspecific binding of immunoglobulins (especially in cats with autoimmune disease) or from residual maternal antibodies in kittens tested before 8 weeks of age [4, 5]. False negatives are most common during the early eclipse phase (first 2 weeks post infection) or in regressive infection where antigenemia has resolved.

Prevalence and Risk Factors: Global Perspectives

The prevalence of FeLV p27 antigenemia varies geographically and with population demographics. Molecular detection of p27 by ELISA has been used in numerous cross-sectional surveys.

In Hong Kong, Beatty et al. (2024) reported a FeLV p27 prevalence of 6.8% among community cats and 2.1% among client-owned cats, with higher odds in male cats and those with free-roaming access [1]. In southern Brazil, Biezus et al. (2023) found a prevalence of 14.1% in a mixed population of healthy and sick cats, and further documented that p27-positive cats had significantly lower hematocrit and total leukocyte counts compared to negative cats [2]. In Thailand, Sprißler et al. (2021) reported a prevalence of 6.2% among healthy cats presenting for routine vaccination, with risk factors including multi-cat households and outdoor lifestyle [4]. In Zimbabwe, Muchaamba et al. (2014) observed a prevalence of 5.0% in Harare and noted that entire (unneutered) male cats were overrepresented among p27-positive animals [7].

Table 2: FeLV p27 Antigen Prevalence in Selected Studies Using ELISA

Application in Treatment Monitoring

p27 ELISA is also used to monitor the efficacy of antiviral therapy. In a trial of azidothymidine (AZT) combined with human interferon-alpha in naturally infected cats, Stuetzer et al. (2013) demonstrated that a reduction in p27 antigenemia (measured by serial ELISA) correlated with clinical improvement, although some cats remained p27-positive throughout the treatment period [8]. Serial p27 quantification provides a noninvasive surrogate marker for viral load in clinical settings where PCR is unavailable.

Limitations and Complementary Diagnostics

The p27 ELISA has several inherent limitations. It cannot distinguish between acute infection and persistent infection without serial sampling. It does not detect provirus; therefore, cats with regressive infection (p27-negative, proviral DNA-positive) will be missed if ELISA is the sole screening method [2, 3]. For this reason, many reference laboratories now combine p27 ELISA with proviral PCR to achieve comprehensive diagnostic coverage. Additionally, the assay does not differentiate between FeLV subgroups (A, B, C, and T), although subgroup determination is rarely required for clinical management.

Saliva-based ELISAs offer convenience and reduced stress for the cat, but they may have slightly lower sensitivity due to lower antigen concentration and the presence of proteases in oral fluid [6]. It remains essential to confirm any positive saliva result with a serum or plasma ELISA.

Conclusions

The ELISA for FeLV p27 antigen remains the most widely used and well-validated serological test for feline leukemia virus infection. Its high sensitivity and specificity, combined with ease of use in both reference laboratories and point-of-care settings, make it an indispensable tool in feline medicine. Proper diagnostic interpretation requires an understanding of FeLV pathogenesis, particularly the distinction between progressive and regressive infection, and the use of confirmatory testing algorithms. The integration of p27 ELISA with molecular methods such as proviral PCR provides the most complete assessment of FeLV status.

References

[1] Beatty JA, Choi YR, Nekouei O, et al. Epidemiology of Pathogenic Retroviruses and Domestic Cat Hepadnavirus in Community and Client-Owned Cats in Hong Kong. Viruses. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38399943/

[2] Biezus G, Grima de Cristo T, da Silva Casa M, et al. Progressive and regressive infection with feline leukemia virus (FeLV) in cats in southern Brazil: Prevalence, risk factors associated, clinical and hematologic alterations. Prev Vet Med. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37209619/

[3] Lutz H, Pedersen NC, Theilen GH. Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am J Vet Res. 1983. URL: https://pubmed.ncbi.nlm.nih.gov/6316819/ --- *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[4] Sprißler F, Jongwattanapisan P, Luengyosluechakul S, et al. Prevalence and Risk Factors of Feline Immunodeficiency Virus and Feline Leukemia Virus Infection in Healthy Cats in Thailand. Front Vet Sci. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/35211532/

[5] Lopez NA, Jacobson RH, Scarlett JM, et al. Sensitivity and specificity of blood test kits for feline leukemia virus antigen. J Am Vet Med Assoc. 1989. URL: https://pubmed.ncbi.nlm.nih.gov/2551864/

[6] Lewis MG, Wright KA, Lafrado LJ, et al. Saliva as a source of feline leukemia virus antigen for diagnosis of disease. J Clin Microbiol. 1987. URL: https://pubmed.ncbi.nlm.nih.gov/3038950/

[7] Muchaamba F, Mutiringindi TH, Tivapasi MT, et al. A survey of feline leukaemia virus infection of domestic cats from selected areas in Harare, Zimbabwe. J S Afr Vet Assoc. 2014. URL: https://pubmed.ncbi.nlm.nih.gov/25686080/

[8] Stuetzer B, Brunner K, Lutz H, et al. A trial with 3'-azido-2',3'-dideoxythymidine and human interferon-α in cats naturally infected with feline leukaemia virus. J Feline Med Surg. 2013. URL: https://pubmed.ncbi.nlm.nih.gov/23321692/

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.